| Journal | Multiple sclerosis and related disorders |
| Study Type | Clinical Study |
| Population | Human participants |
With 72% of multiple sclerosis patients experiencing polypharmacy, clinicians need evidence-based frameworks for managing complex medication regimens. This study provides critical baseline data on medication burden in MS patients receiving rehabilitation, highlighting the scope of potential drug interactions and adverse effects.
This retrospective cross-sectional study analyzed 475 MS patients at Canada’s largest MS clinic between 2021-2023, finding that 72% had polypharmacy (5+ medications) and 25% had hyper-polypharmacy (10+ medications). The study examined correlations between medication burden and sociodemographic, clinical, and behavioral factors in an outpatient rehabilitation setting. While the findings establish the prevalence of complex medication regimens in this population, the cross-sectional design limits causal inference about contributing factors.
“These numbers reflect what I see clinically – MS patients often arrive with medication lists that require careful review for interactions and optimization opportunities. The high prevalence of polypharmacy underscores why comprehensive medication reconciliation must be standard practice in MS care.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How common is polypharmacy among people with multiple sclerosis in rehabilitation settings?
- What factors increase the risk of polypharmacy in MS patients?
- What are the clinical concerns with polypharmacy in MS patients?
- Should clinicians routinely assess medication burden in MS patients entering rehabilitation?
- How can rehabilitation teams address polypharmacy in MS patients?
FAQ
How common is polypharmacy among people with multiple sclerosis in rehabilitation settings?
This study found that 72.2% of people with MS receiving outpatient rehabilitation had polypharmacy (≥5 medications), with 25.2% having hyper-polypharmacy (>10 medications). This high prevalence reflects the complex medication needs of MS patients managing both their primary condition and associated comorbidities.
What factors increase the risk of polypharmacy in MS patients?
While the study examined sociodemographic, clinical, and comorbidity factors as correlates of polypharmacy, specific risk factors would need to be detailed from the regression analysis results. The presence of multiple comorbidities requiring pharmacologic intervention appears to be a primary driver of increased medication use in this population.
What are the clinical concerns with polypharmacy in MS patients?
Polypharmacy is associated with numerous adverse outcomes including increased risk of drug interactions, medication errors, adverse drug reactions, and reduced medication adherence. In MS patients who may already experience cognitive symptoms, these risks may be particularly problematic for medication management.
Should clinicians routinely assess medication burden in MS patients entering rehabilitation?
Given that over 70% of MS patients in rehabilitation settings have polypharmacy, routine medication review should be a standard part of care. This assessment can identify opportunities for medication optimization, potential drug interactions, and strategies to improve medication management during rehabilitation.
How can rehabilitation teams address polypharmacy in MS patients?
Rehabilitation teams should collaborate with prescribing physicians to conduct comprehensive medication reviews, identify potentially inappropriate medications, and implement strategies to optimize therapeutic regimens. Patient education about medication management and monitoring for adverse effects should also be integrated into rehabilitation care plans.